Vivanza Biosciences (BOM:530057) Cyclically Adjusted Revenue per Share: ₹6.24 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530057 Vivanza Biosciences Ltd BOM:530057
51 GF Score
Price ₹1.82
GF Value ₹23.40
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Vivanza Biosciences Cyclically Adjusted Revenue per Share?

Vivanza Biosciences BOM:530057 +5.20% 51 Cyclically Adjusted Revenue per Share is ₹6.24 as of Jun. 2026. GuruFocus rates BOM:530057 with a GF Score™ of 51/100 and a GF Value™ of ₹23.40 (Possible Value Trap). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Vivanza Biosciences's adjusted revenue per share for the three months ended in Jun. 2026 was ₹2.533. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹6.24 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Vivanza Biosciences's average Cyclically Adjusted Revenue Growth Rate was 83.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 31.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 21.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Vivanza Biosciences was 31.60% per year. The lowest was 13.10% per year. And the median was 17.70% per year.

As of today (2026-08-27), Vivanza Biosciences's current stock price is ₹1.82. Vivanza Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹6.24. Vivanza Biosciences's Cyclically Adjusted PS Ratio of today is 0.29.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vivanza Biosciences was 10.00. The lowest was 0.28. And the median was 2.91.


Vivanza Biosciences  (BOM:530057) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vivanza Biosciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.82/6.24
=0.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vivanza Biosciences was 10.00. The lowest was 0.28. And the median was 2.91.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Vivanza Biosciences Cyclically Adjusted Revenue per Share Related Terms


Vivanza Biosciences Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Vivanza Biosciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivanza Biosciences Cyclically Adjusted Revenue per Share Chart

Vivanza Biosciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.23 2.64 3.31 3.23 6.02

Vivanza Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.41 4.86 5.98 6.02 6.24

BOM:530057 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vivanza Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivanza Biosciences Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vivanza Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vivanza Biosciences's Cyclically Adjusted PS Ratio falls into.


BOM:530057
51GF Score
Vivanza Biosciences Ltd BOM:530057
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivanza Biosciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vivanza Biosciences's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.533/167.3573*167.3573
=2.533

Current CPI (Jun. 2026) = 167.3573.

Vivanza Biosciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.184 105.961 0.291
201612 0.120 105.196 0.191
201703 0.631 105.196 1.004
201706 0.643 107.109 1.005
201709 0.133 109.021 0.204
201712 0.510 109.404 0.780
201803 0.307 109.786 0.468
201806 0.262 111.317 0.394
201809 0.055 115.142 0.080
201812 0.017 115.142 0.025
201903 0.335 118.202 0.474
201906 0.126 120.880 0.174
201909 0.002 123.175 0.003
201912 0.773 126.235 1.025
202003 1.502 124.705 2.016
202006 0.171 127.000 0.225
202009 0.558 130.118 0.718
202012 1.009 130.889 1.290
202103 1.500 131.771 1.905
202106 0.056 134.084 0.070
202109 0.705 135.847 0.869
202112 0.383 138.161 0.464
202203 1.470 138.822 1.772
202206 0.587 142.347 0.690
202209 0.340 144.661 0.393
202212 1.406 145.763 1.614
202303 1.915 146.865 2.182
202306 2.241 150.280 2.496
202309 2.043 151.492 2.257
202312 1.593 152.924 1.743
202403 1.110 153.035 1.214
202406 0.642 155.789 0.690
202409 0.750 157.882 0.795
202412 0.351 158.323 0.371
202503 0.121 157.552 0.129
202506 2.055 159.755 2.153
202509 13.768 162.289 14.198
202512 11.579 163.281 11.868
202603 1.553 164.272 1.582
202606 2.533 167.357 2.533

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹6.24 mean?
Vivanza Biosciences (BOM:530057) has a Cyclically Adjusted Revenue per Share of ₹6.24 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vivanza Biosciences and its competitors.
Is Vivanza Biosciences' Cyclically Adjusted Revenue per Share too high?
Vivanza Biosciences' current Cyclically Adjusted Revenue per Share is ₹6.24. Overall, Vivanza Biosciences has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vivanza Biosciences' Cyclically Adjusted Revenue per Share compare to ZTS?
Vivanza Biosciences' Cyclically Adjusted Revenue per Share of ₹6.24 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vivanza Biosciences and its competitors. Vivanza Biosciences's current Cyclically Adjusted Revenue per Share is ₹6.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivanza Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Vivanza Biosciences (BOM:530057) is currently considered Possible Value Trap. The stock's GF Value™ is ₹23.40, compared to a current price of ₹1.82 — trading 92.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹6.24. Vivanza Biosciences' overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Vivanza Biosciences (BOM:530057), the current Cyclically Adjusted Revenue per Share is ₹6.24 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vivanza Biosciences (BOM:530057) Overvalued in 2026?

Based on GuruFocus' analysis, Vivanza Biosciences stock appears to be undervalued. The current stock price of ₹1.82 is trading 92.2% below its estimated GF Value™ of ₹23.40. GuruFocus considers Vivanza Biosciences to be Possible Value Trap.

Key valuation signals for BOM:530057:

  • Cyclically Adjusted Revenue per Share: ₹6.24
  • GF Value™: ₹23.40 vs. price of ₹1.82 (92.2% below fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the BOM:530057 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vivanza Biosciences Business Description

Address S.G. Highway, 403/TF, Sarthik II, Opposite Rajpath Club, Bodakdev, Ahmedabad, GJ, IND, 380054
Vivanza Biosciences Ltd is a pharmaceutical company. Its core focus areas include research and development, manufacturing, and the distribution of a wide range of pharma and pharmaceutical products. The company's product portfolio includes Medical examination gloves, Injections, Veterinary feeds, and others.
51GF Score

Get the complete analysis for BOM:530057

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1.82
Price
₹23.40
GF Value